Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

@article{Wassmann2005EarlyMR,
  title={Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).},
  author={Barbara Wassmann and Heike Pfeifer and Michael E. Stadler and Martin Bornha{\"u}ser and Gesine Bug and Urban J Scheuring and Patrick Brueck and Matthias Stelljes and Rainer Schwerdtfeger and Nadezda Basara and Jolanta B. Perz and Donald Bunjes and Georg J Ledderose and Rolf Mahlberg and Anja Binckebanck and Harald Gschaidmeier and Dieter Hoelzer and Oliver G Ottmann},
  journal={Blood},
  year={2005},
  volume={106 2},
  pages={
          458-63
        }
}
In adult Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), minimal residual disease (MRD) after stem cell transplantation (SCT) is associated with a relapse probability exceeding 90%. Starting imatinib in the setting of MRD may decrease this high relapse rate. In this prospective multicenter study, 27 Ph+ ALL patients received imatinib upon detection of MRD after SCT. Bcr-abl transcripts became undetectable in 14 (52%) of 27 patients, after a median of 1.5 months (0.9-3.7… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 91 CITATIONS, ESTIMATED 12% COVERAGE

Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia

  • Current Hematologic Malignancy Reports
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia

Mehrdad Hefazi, Mark R Litzow
  • Blood and lymphatic cancer : targets and therapy
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2005
2019

CITATION STATISTICS

  • 1 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

In molecular relapse after stem cell transplantation (SCT) for Ph ALL, imatinib can induce sustained molecular remissions

B Wassmann, H Pfeifer, UJ Scheuring
  • MRD IN POSTTRANSPLANTATION Ph ALL 463 BLOOD,
  • 2003